Why NGL Fine Chem Share Price is Falling

The Indian pharmaceutical sector is one of the fastest-growing industries in the country.

It is a global leader in generic drug manufacturing, supplying affordable medicines to over 200 countries. With a strong R&D base, India has also made significant progress in developing complex drugs and biosimilars.

NGL Fine Chem is a key player in this thriving industry. It specialises in manufacturing active pharmaceutical ingredients (APIs) for veterinary and human use. The company serves both domestic and international markets, leveraging India's strong pharma ecosystem.

Recently, the company' stock has come under investor focus. Its share price has been under pressure ever since it declared its quarterly results.

In the past five days, NGL Fine Chem share price has tumbled 32.5%.

Let's take a closer look at the company's financials to understand why its stock is falling.

Weak Quarterly Results

NGL Fine Chem reported a weak financial performance for the December 2024 quarter, leading to a sharp fall in its share price. Rising expenses and lower revenue have impacted profitability, raising investor concerns.

The company's net profit for the quarter stood at 12.8 million (m), a significant decline from Rs 100.3 m reported in the same period last year.

This steep drop in profit is mainly due to higher costs and lower revenue growth. Increased raw material prices and operational expenses have reduced margins, putting pressure on earnings.

Total revenue for the quarter was Rs 890 m, a sharp decline from Rs 916.3 m in the previous year. The decline in revenue suggests weaker demand or pricing pressure in key markets. A slowdown in export sales and competitive pricing in the domestic market have contributed to this drop.

Meanwhile, total expenses rose to Rs 877 m, a 13.5% increase from Rs 773 m in the year-ago period. Higher raw material costs and employee expenses have significantly increased the company's spending. The rising cost burden has further squeezed profit margins.

Due to the weak financial performance, investor sentiment has turned negative leading to a heavy sell-off in the stock.

What Next?

NGL Fine Chem is facing short-term challenges, but the company is focusing on long-term growth strategies. The decline in revenue and profit has been driven by lower demand, pricing pressures, and rising costs.

However, the company is actively working to overcome these hurdles and strengthen its position in the market.

The company has planned a major expansion to scale up production. A greenfield expansion at Tarapur is in progress, with an estimated Rs 1.6 billion (bn) investment.

This expansion will increase production capacity by 50%, allowing the company to meet rising demand for new products. Civil construction is underway, and Rs 0.8 bn has already been invested in the project.

Additionally, NGL Fine Chem has completed an expansion in its subsidiary, Macrotech, which has added new capacities for intermediates. Commercial production from this expansion has already started, which could contribute to revenue growth in the coming quarters.

The company is also strengthening its global presence, with a focus on expanding its footprint in the US and European markets. While non-regulated markets remain a key revenue source, establishing a stronger presence in regulated markets will help drive sustainable growth.

Despite the current pressure on margins, the company remains committed to cost efficiency and operational improvements. With 95% in-house manufacturing and backward integration, it aims to maintain cost competitiveness.

NGL Fine Chem is also focusing on product diversification to reduce dependence on a few key APIs. The company has a pipeline of new products that it aims to introduce in the coming years. This will help in mitigating risks from market fluctuations and broadening revenue streams.

Additionally, the company is working on optimizing operational efficiency by improving its manufacturing processes. Investments in automation and process improvements are expected to enhance productivity and reduce costs over time.

The management remains confident that the ongoing capacity expansions and strategic initiatives will help the company regain growth momentum.

However, the near-term performance will depend on demand recovery and stabilizing pricing trends in key markets.

Investors should evaluate the company's fundamentals, corporate governance, and valuations of the stock as key factors when conducting due diligence before making investment decisions.

How NGL Fine Chem Share Price has Performed Recently

In the past five days, NGL Fine Chem share price has tumbled 32.5%. In the last month, it has slipped 23.6%.

In the last six months, its share price has crashed 52%. Additionally, in the last one year, its share price has tumbled 31.1%.

The stock touched its 52-week high of Rs 2,822.5 on 25 April 2024 and a 52-week low of Rs 1,202.1 on 12 February 2025.

About NGL Fine Chem

Established in 1981, NGL Fine Chem manufactures human and veterinary bulk drugs, intermediates, and formulations. It primarily deals in animal healthcare products such as antiprotozoal, anthelmintics, and growth promoters.

For more details about the company, you can have a look at NGL Fine Chem company fact sheet and NGL Fine Chem quarterly results on our website.

For a sector overview, read our pharmaceuticals sector report.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...